- Home
- NXGL vs CALC Comparison
NXGL vs CALC Comparison
Compare NXGL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- CALC
- Stock Information
- Founded
- NXGL 1997
- CALC 2011
- Country
- NXGL United States
- CALC United States
- Employees
- NXGL N/A
- CALC N/A
- Industry
- NXGL Medical/Dental Instruments
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- CALC Health Care
- Exchange
- NXGL Nasdaq
- CALC Nasdaq
- Market Cap
- NXGL 19.4M
- CALC 20.9M
- IPO Year
- NXGL 2021
- CALC N/A
- Fundamental
- Price
- NXGL $2.60
- CALC $1.99
- Analyst Decision
- NXGL
- CALC Strong Buy
- Analyst Count
- NXGL 0
- CALC 3
- Target Price
- NXGL N/A
- CALC $16.33
- AVG Volume (30 Days)
- NXGL 28.3K
- CALC 33.2K
- Earning Date
- NXGL 05-13-2025
- CALC 05-14-2025
- Dividend Yield
- NXGL N/A
- CALC N/A
- EPS Growth
- NXGL N/A
- CALC N/A
- EPS
- NXGL N/A
- CALC N/A
- Revenue
- NXGL $10,228,000.00
- CALC N/A
- Revenue This Year
- NXGL $51.39
- CALC N/A
- Revenue Next Year
- NXGL $36.14
- CALC N/A
- P/E Ratio
- NXGL N/A
- CALC N/A
- Revenue Growth
- NXGL 116.01
- CALC N/A
- 52 Week Low
- NXGL $1.84
- CALC $1.43
- 52 Week High
- NXGL $5.10
- CALC $6.02
- Technical
- Relative Strength Index (RSI)
- NXGL 42.93
- CALC 60.81
- Support Level
- NXGL $2.49
- CALC $1.86
- Resistance Level
- NXGL $2.84
- CALC $2.04
- Average True Range (ATR)
- NXGL 0.22
- CALC 0.14
- MACD
- NXGL 0.01
- CALC 0.04
- Stochastic Oscillator
- NXGL 13.51
- CALC 76.01
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.